Novartis, U.S. regulators agree to malaria drug trial against COVID-19

Novartis has reached an agreement with U.S. regulators to hold a randomized trial of generic malaria drug hydroxychloroquine against COVID-19 disease in 440 hospitalised patients, the Swiss drugmaker said on Monday.